"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
| Descriptor ID |
D013792
|
| MeSH Number(s) |
D02.241.223.805.810.800 D03.383.621.808.800 D03.633.100.513.750.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thalidomide".
Below are MeSH descriptors whose meaning is more specific than "Thalidomide".
This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 6 | 1 | 7 |
| 2001 | 3 | 1 | 4 |
| 2002 | 5 | 3 | 8 |
| 2003 | 5 | 5 | 10 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 4 | 7 |
| 2006 | 6 | 4 | 10 |
| 2007 | 9 | 3 | 12 |
| 2008 | 7 | 3 | 10 |
| 2009 | 10 | 3 | 13 |
| 2010 | 8 | 10 | 18 |
| 2011 | 8 | 9 | 17 |
| 2012 | 8 | 9 | 17 |
| 2013 | 10 | 13 | 23 |
| 2014 | 10 | 7 | 17 |
| 2015 | 5 | 12 | 17 |
| 2016 | 7 | 6 | 13 |
| 2017 | 5 | 5 | 10 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thalidomide" by people in Profiles.
-
Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer. 2024 Jun 04; 32(7):407.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). J Clin Immunol. 2023 05; 43(4):780-793.
-
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 2022 Dec; 27(1):204-207.
-
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology. 2022 Dec; 27(1):691-699.
-
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood Cancer J. 2022 11 29; 12(11):162.
-
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763.
-
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial. Blood Cancer J. 2022 01 24; 12(1):9.
-
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022 Jan; 23(1):37-50.
-
Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 02; 7(6).